Literature DB >> 24358872

High-resolution view of compound promiscuity.

Ye Hu1, Jürgen Bajorath1.   

Abstract

Compound promiscuity is defined as the ability of a small molecule to specifically interact with multiple biological targets. So-defined promiscuity is relevant for drug discovery because it provides the molecular basis of polypharmacology, which is increasingly implicated in the therapeutic efficacy of drugs. Recent studies have analyzed different aspects of compound promiscuity on the basis of currently available activity data. In this commentary, we present take-home messages from these studies augmented with new results to generate a detailed picture of compound promiscuity that might serve as a reference for further discussions and research activities.

Entities:  

Year:  2013        PMID: 24358872      PMCID: PMC3799544.1          DOI: 10.12688/f1000research.2-144.v1

Source DB:  PubMed          Journal:  F1000Res        ISSN: 2046-1402


  14 in total

1.  Global mapping of pharmacological space.

Authors:  Gaia V Paolini; Richard H B Shapland; Willem P van Hoorn; Jonathan S Mason; Andrew L Hopkins
Journal:  Nat Biotechnol       Date:  2006-07       Impact factor: 54.908

2.  Data completeness--the Achilles heel of drug-target networks.

Authors:  Jordi Mestres; Elisabet Gregori-Puigjané; Sergi Valverde; Ricard V Solé
Journal:  Nat Biotechnol       Date:  2008-09       Impact factor: 54.908

3.  Drug-target network.

Authors:  Muhammed A Yildirim; Kwang-Il Goh; Michael E Cusick; Albert-László Barabási; Marc Vidal
Journal:  Nat Biotechnol       Date:  2007-10       Impact factor: 54.908

4.  Growth of ligand-target interaction data in ChEMBL is associated with increasing and activity measurement-dependent compound promiscuity.

Authors:  Ye Hu; Jürgen Bajorath
Journal:  J Chem Inf Model       Date:  2012-09-28       Impact factor: 4.956

5.  What is the likelihood of an active compound to be promiscuous? Systematic assessment of compound promiscuity on the basis of PubChem confirmatory bioassay data.

Authors:  Ye Hu; Jürgen Bajorath
Journal:  AAPS J       Date:  2013-04-19       Impact factor: 4.009

Review 6.  Systems approaches to polypharmacology and drug discovery.

Authors:  Aislyn D W Boran; Ravi Iyengar
Journal:  Curr Opin Drug Discov Devel       Date:  2010-05

7.  DrugBank 3.0: a comprehensive resource for 'omics' research on drugs.

Authors:  Craig Knox; Vivian Law; Timothy Jewison; Philip Liu; Son Ly; Alex Frolkis; Allison Pon; Kelly Banco; Christine Mak; Vanessa Neveu; Yannick Djoumbou; Roman Eisner; An Chi Guo; David S Wishart
Journal:  Nucleic Acids Res       Date:  2010-11-08       Impact factor: 16.971

8.  ChEMBL: a large-scale bioactivity database for drug discovery.

Authors:  Anna Gaulton; Louisa J Bellis; A Patricia Bento; Jon Chambers; Mark Davies; Anne Hersey; Yvonne Light; Shaun McGlinchey; David Michalovich; Bissan Al-Lazikani; John P Overington
Journal:  Nucleic Acids Res       Date:  2011-09-23       Impact factor: 16.971

9.  PubChem's BioAssay Database.

Authors:  Yanli Wang; Jewen Xiao; Tugba O Suzek; Jian Zhang; Jiyao Wang; Zhigang Zhou; Lianyi Han; Karen Karapetyan; Svetlana Dracheva; Benjamin A Shoemaker; Evan Bolton; Asta Gindulyte; Stephen H Bryant
Journal:  Nucleic Acids Res       Date:  2011-12-02       Impact factor: 16.971

Review 10.  Targeting the cancer kinome through polypharmacology.

Authors:  Zachary A Knight; Henry Lin; Kevan M Shokat
Journal:  Nat Rev Cancer       Date:  2010-02       Impact factor: 60.716

View more
  17 in total

1.  Structural and Activity Profile Relationships Between Drug Scaffolds.

Authors:  Ye Hu; Jürgen Bajorath
Journal:  AAPS J       Date:  2015-02-20       Impact factor: 4.009

2.  Systematic computational identification of promiscuity cliff pathways formed by inhibitors of the human kinome.

Authors:  Filip Miljković; Martin Vogt; Jürgen Bajorath
Journal:  J Comput Aided Mol Des       Date:  2019-03-26       Impact factor: 3.686

3.  Structure-Promiscuity Relationship Puzzles-Extensively Assayed Analogs with Large Differences in Target Annotations.

Authors:  Ye Hu; Swarit Jasial; Erik Gilberg; Jürgen Bajorath
Journal:  AAPS J       Date:  2017-03-06       Impact factor: 4.009

4.  Enhancing Molecular Promiscuity Evaluation Through Assay Profiles.

Authors:  Sorin Avram; Ramona Curpan; Alina Bora; Cristian Neanu; Liliana Halip
Journal:  Pharm Res       Date:  2018-10-18       Impact factor: 4.200

5.  Many approved drugs have bioactive analogs with different target annotations.

Authors:  Ye Hu; Eugen Lounkine; Jürgen Bajorath
Journal:  AAPS J       Date:  2014-05-29       Impact factor: 4.009

6.  Data structures for computational compound promiscuity analysis and exemplary applications to inhibitors of the human kinome.

Authors:  Filip Miljković; Jürgen Bajorath
Journal:  J Comput Aided Mol Des       Date:  2019-12-02       Impact factor: 3.686

7.  Promiscuity progression of bioactive compounds over time.

Authors:  Ye Hu; Swarit Jasial; Jürgen Bajorath
Journal:  F1000Res       Date:  2015-05-13

Review 8.  Exploring compound promiscuity patterns and multi-target activity spaces.

Authors:  Ye Hu; Disha Gupta-Ostermann; Jürgen Bajorath
Journal:  Comput Struct Biotechnol J       Date:  2014-01-29       Impact factor: 7.271

9.  Activity artifacts in drug discovery and different facets of compound promiscuity.

Authors:  Jürgen Bajorath
Journal:  F1000Res       Date:  2014-10-03

10.  Monitoring drug promiscuity over time.

Authors:  Ye Hu; Jürgen Bajorath
Journal:  F1000Res       Date:  2014-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.